Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab with Chemoradiotherapy in LS-SCLC
NCT07103408Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2025
- Primary completion
- Sep 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in small cell lung cancer (SCLC), sponsored by Sun Yat-sen University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07103408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103408.